BNP/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.12.24 | Delayed Deutsche Boerse AG 07:50:12 20/06/2024 pm IST | ||
| 0.004 EUR | +300.00% |
|
| Current month | -66.67% | ||
| 3 months | -50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 0.004 | +300.00% |
| 19/24/19 | 0.001 | -80.00% |
| 18/24/18 | 0.005 | 0.00% |
| 17/24/17 | 0.005 | 0.00% |
| 14/24/14 | 0.005 | +25.00% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 07:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE8957 |
| ISIN | DE000PE89570 |
| Date issued | 16/02/2023 |
| Strike | 70 $ |
| Maturity | 20/12/2024 (183 Days) |
| Parity | 10 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.03 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.087 € |
| Spread % | 95.60% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Warrants
- Warrant
